Gianluca Caiazzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2977126/publications.pdf

Version: 2024-02-01

414414 361413 1,102 52 20 32 citations h-index g-index papers 61 61 61 1802 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. Heart, 2022, 108, 458-466.	2.9	28
2	Severe Inveterate Stent Underexpansion Treated With OCT-Guided Excimer Laser-Based PCI. Cardiovascular Revascularization Medicine, 2021, 28, 153-157.	0.8	O
3	Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary noâ€reflow during primary PCI: The RESTORE observational study. Catheterization and Cardiovascular Interventions, 2021, 97, 602-611.	1.7	20
4	Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry. Biomedicine and Pharmacotherapy, 2021, 138, 111469.	5.6	3
5	Comparison Between Sirolimus- and Paclitaxel-Coated Balloon for Revascularization of Coronary Arteries: The SIRPAC (SIRolimus-PAClitaxel) Study. Cardiovascular Revascularization Medicine, 2021, 28, 1-6.	0.8	14
6	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. Atherosclerosis, 2021, 332, 48-54.	0.8	28
7	Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. Journal of Cardiovascular Medicine, 2021, 22, 94-100.	1.5	29
8	Renin-Angiotensin System inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID Pandemic. Diabetes Epidemiology and Management, 2021, 4, 100022.	0.8	1
9	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Comer PatiEnts: the REDUCE registry. Coronary Artery Disease, 2021, 32, 281-287.	0.7	2
10	State of the Art. Cardiology Clinics, 2020, 38, 563-573.	2.2	24
11	Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention. Current Atherosclerosis Reports, 2020, 22, 76.	4.8	4
12	Sirolimus-Eluting Balloon for the Treatment of Coronary Lesions in Complex ACS Patients: The SELFIE Registry. Journal of Interventional Cardiology, 2020, 2020, 1-7.	1.2	7
13	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. Journal of the American College of Cardiology, 2020, 76, 2321-2330.	2.8	154
14	Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated With the COVID-19 Outbreak. Circulation, 2020, 141, 2035-2037.	1.6	107
15	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovascular Diabetology, 2020, 19, 215.	6.8	30
16	Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor. BioMed Research International, 2016, 2016, 1-5.	1.9	57
17	Three-dimensional optical coherence tomography reconstruction of a long coronary artery dissection. Journal of Cardiovascular Medicine, 2016, 17, e107-e108.	1.5	O
18	Bioresorbable vascular scaffold restenosis. Journal of Cardiovascular Medicine, 2016, 17, e132-e135.	1.5	1

#	Article	IF	Citations
19	Is high pressure postdilation safe in bioresorbable vascular scaffolds? Optical coherence tomography observations after noncompliant balloons inflated at more than 24 atmospheres. Catheterization and Cardiovascular Interventions, 2016, 87, 839-846.	1.7	23
20	Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaffolds. International Journal of Cardiology, 2016, 221, 352-358.	1.7	24
21	Predictors of Bioresorbable Everolimus-Eluting Scaffold Failure at Intravascular Ultrasound Examination. JACC: Cardiovascular Interventions, 2016, 9, 1970-1971.	2.9	O
22	Indications and immediate and longâ€term results of a novel pericardium covered stent graft: Consecutive 5 year single center experience. Catheterization and Cardiovascular Interventions, 2016, 87, 712-719.	1.7	19
23	Nonatherosclerotic Coronary Artery Narrowing. JACC: Cardiovascular Imaging, 2016, 9, 317-320.	5.3	6
24	Coronary covered stents. EuroIntervention, 2016, 12, 1288-1295.	3.2	51
25	Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances. EuroIntervention, 2016, 12, e566-e573.	3.2	15
26	Bioresorbable vascular scaffold radial expansion and conformation compared to a metallic platform: insights from in vitro expansion in a coronary artery lesion model. EuroIntervention, 2016, 12, 834-844.	3.2	12
27	Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments. EuroIntervention, 2016, 11, 1389-1399.	3.2	35
28	TCT-512 Bioabsorbable Vascular Scaffold Radial Expansion and Conformation Compared to a Metallic platform: Insights from In-vitro Expansion in a Coronary Artery Lesion Model. Journal of the American College of Cardiology, 2015, 66, B209.	2.8	0
29	The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovascular Disorders, 2015, 15, 169.	1.7	20
30	Near-infrared spectroscopy-intravascular ultrasound: scientific basis and clinical applications. European Heart Journal Cardiovascular Imaging, 2015, 16, jev208.	1.2	31
31	CRT-404 Is High Pressure Post-Dilation Safe In Bioresorbable Vascular Scaffolds? Optical Coherence Tomography Observations after Non-Compliant Balloons Inflated at more than 24 Atmospheres. JACC: Cardiovascular Interventions, 2015, 8, S37.	2.9	0
32	Absorb bioresorbable vascular scaffold: What have we learned after 5years of clinical experience?. International Journal of Cardiology, 2015, 201, 129-136.	1.7	51
33	Stent deformation at the edge of a high pressure balloon. Cardiovascular Revascularization Medicine, 2015, 16, 508-509.	0.8	1
34	TCT-427 Safety and Efficacy of The ProStar XL Percutaneous Vascular Closure System for Transfemoral Transcatheter Aortic Valve Replacement (TAVR): a Single Center Six-year Experience. Journal of the American College of Cardiology, 2015, 66, B174.	2.8	0
35	TCT-514 Absorb Vs DESolve: an optical coherence tomography comparison of acute mechanical performances. Journal of the American College of Cardiology, 2015, 66, B210.	2.8	1
36	Three-vessel coronary artery disease evaluation by multimodality imaging with near-infrared spectroscopy (NIRS) plus intravascular ultrasound (IVUS) and optical coherence tomography (OCT). International Journal of Cardiology, 2015, 180, 21-29.	1.7	2

#	Article	IF	CITATIONS
37	The instantaneous wave-free ratio (iFR) for evaluation of non-culprit lesions in patients with acute coronary syndrome and multivessel disease. International Journal of Cardiology, 2015, 178, 46-54.	1.7	37
38	Biodegradable stents: the golden future of angioplasty?. Lancet, The, 2015, 385, 10-12.	13.7	30
39	Neointimal Proliferation Is Associated With Clinical Restenosis 2 Years After Fully Bioresorbable Vascular Scaffold Implantation. Circulation: Cardiovascular Imaging, 2014, 7, 755-757.	2.6	18
40	Administration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndrome. Circulation: Cardiovascular Interventions, 2014, 7, 104-112.	3.9	29
41	Aspiration Thrombectomy. Journal of the American College of Cardiology, 2014, 63, 2052-2053.	2.8	13
42	Left radial access for percutaneous coronary procedures: From neglected to performer? A meta-analysis of 14 studies including 7603 procedures. International Journal of Cardiology, 2014, 171, 66-72.	1.7	23
43	Influence of multimodality coronary imaging on revascularization strategy. International Journal of Cardiology, 2014, 177, 515-516.	1.7	1
44	Response to Letter Regarding, "Administration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndrome― Circulation: Cardiovascular Interventions, 2014, 7, 634-634.	3.9	0
45	Intracoronary Versus Intravenous Abciximab Bolus Administration. Journal of the American College of Cardiology, 2014, 63, 1340-1341.	2.8	8
46	Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: A meta-analysis of clinical trials. International Journal of Cardiology, 2013, 168, 1298-1305.	1.7	18
47	What accounts for the higher clinical efficacy of intracoronary abciximab?. International Journal of Cardiology, 2013, 168, 4410.	1.7	3
48	Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial. Circulation: Cardiovascular Interventions, 2011, 4, 121-129.	3.9	41
49	Effects of AT1 Receptor Antagonism With Candesartan on Endothelial Function in Patients With Hypertension and Coronary Artery Disease. Journal of Clinical Hypertension, 2009, 11, 260-265.	2.0	21
50	Rest-redistribution 201-Thallium single photon emission computed tomography predicts myocardial infarction and cardiac death in patients with ischemic left ventricular dysfunction. Journal of Cardiovascular Medicine, 2009, 10, 122-128.	1.5	1
51	Differences in Echocardiographic Assessment with Standard Doppler and Tissue Doppler Imaging of Left Ventricular Filling Pressure in Idiopathic and Ischemic Dilated Cardiomyopathy. Echocardiography, 2008, 25, 683-691.	0.9	2
52	Relation of Brachial Artery Flow-Mediated Vasodilation to Significant Coronary Artery Disease in Patients With Peripheral Arterial Disease. American Journal of Cardiology, 2005, 96, 1337-1341.	1.6	53